Age-Related Macular Degeneration

AMD: Avastin vs. Lucentis Treatment for Wet Macular Degeneration (AMD)

Wissenschaftspreis für Dr. Aysegül Tura Aktuell: Deutsche Ophthalmologische Gesellschaft zeichnet hochkarätige Veröffentlichungen zu neuen Therapieansätzen bei Netzhauterkrankungen aus: Wissenschaftspreis der Stiftung Auge für Dr. Aysegül Tura (Universitäts-Augenklinik Lübeck)

Durchsuchen Sie hier die Seiten zur altersbedingten Makuladegeneration:

Geben Sie beliebige Suchbegriffe ein (AMD, Therapie, Diagnose, Nahrungsergänzungsmittel...)

Genentech USA, Inc.: Lucentis


November 23, 2011

Regeneron Challenges Genentech's Lucentis

Regeneron Pharmaceuticals won approval for its macular degeneration drug Eylea, putting the drug into competition with Genentech’s Lucentis and Avastin.

read more: Regeneron Challenges Genentech's Lucentis

07/10/2011 InPharm

Novartis cuts Lucentis price amid growing pressure

Novartis has been forced to cut the Swiss price of its eye drug Lucentis by 30% after sharp negotiations with the government.

read more: Novartis cuts Lucentis price amid growing pressure

04.10.2011 Le Matin

BURKHALTER FAIT RECULER NOVARTIS

Novartis ne le claironne pas. Mais depuis le début de ce mois, le géant pharmaceutique accorde un rabais de 30% sur le Lucentis, le seul traitement officiellement reconnu contre la dégénérescence maculaire humide liée à l'âge (DMLA).

lire la suite: BURKHALTER FAIT RECULER NOVARTIS

September 27, 2011 medcitynews.com

When cheaper isn't better: The case of Avastin, Lucentis and wet AMD

To make a long story short, Avastin is a highly-effective anti-cancer drug. Lucentis is basically the same drug, but it's indicated for an ophthalmic condition: wet age-related macular degeneration. Since Lucentis is injected in the eye only a little bit is needed.

read more: When cheaper isn't better: The case of Avastin, Lucentis and wet AMD

Mar 30, 2011, reuters.com: Lucentis vs Avastin study may feature at May 1-5 congress

Lucentis vs Avastin study may feature at May 1-5 congress

Results of the so-called CATT study comparing Roche (ROG.VX) and Novartis's (NOVN.VX) eye drug Lucentis with low doses of cancer treatment Avastin may be presented at a medical meeting in early May.

read more: Lucentis vs Avastin study may feature at May 1-5 congress

03.11.2010 New York Times: Genentech Offers Secret Rebates for Eye Drug

Genentech Offers Secret Rebates for Eye Drug

Genentech has begun offering secret rebates to eye doctors as an apparent inducement to get them to use more of the company's expensive drug Lucentis rather than a less costly alternative.

read more: Genentech Offers Secret Rebates for Eye Drug

01.10.2010 nature.com: Bevacizumab vs ranibizumab for age-related macular degeneration

Clinical Study

Bevacizumab vs ranibizumab for age-related macular degeneration:

1-year outcomes of a prospective, double-masked randomised clinical trial

read more: Bevacizumab vs ranibizumab for age-related macular degeneration:

13.10.2009 Boston University

BUSM Researchers Find Cancer Drug as Effective and Less Costly than Standard Macular Degeneration Treatment

Investigators from BUSM and the VA Boston Healthcare System have shown, at the six month mark in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

read more: BUSM Researchers Find Cancer Drug as Effective and Less Costly than Standard Macular Degeneration Treatment


Ferienhof am Ostseestrand

Urlaub Ferienhof Glücksburg-Holnis

7 Ferienwohnungen sind in diesem Ferienhof mit Reitbetrieb am Strand Holnis untergebracht. Alle Ferienwohnungen sind mit SAT-TV ausgestattet. Jede Wohnung verfügt über eine gemütliche Eßecke und Sitzgarnitur. Ein Duschbad gehört ebenfalls zu jeder Ferienwohnung. Großer Garten, Grillhütte und Spielplatz sind am Haus!